Publication:
Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-α and 13-cis-retinoic acid: Report of two cases and review of the literature

dc.contributor.authorSurintip Piamsomboonen_US
dc.contributor.authorWichai Termrungruanglerten_US
dc.contributor.authorAndrzej P. Kudelkaen_US
dc.contributor.authorCreighton L. Edwardsen_US
dc.contributor.authorRalph S. Freedmanen_US
dc.contributor.authorClifton F. Mountainen_US
dc.contributor.authorLuis Delclosen_US
dc.contributor.authorMatti S. Aaproen_US
dc.contributor.authorLouis DeCaroen_US
dc.contributor.authorJoseph Biancaen_US
dc.contributor.authorClaire F. Verschraegenen_US
dc.contributor.authorJohn J. Kavanaghen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherUniversity of Texas MD Anderson Cancer Centeren_US
dc.contributor.otherIstituto Europeo di Oncologiaen_US
dc.contributor.otherTexas Heart Instituteen_US
dc.contributor.otherDiagnostic Clinic of Longviewen_US
dc.date.accessioned2018-07-04T07:23:03Z
dc.date.available2018-07-04T07:23:03Z
dc.date.issued1996-01-01en_US
dc.description.abstractRecurrent and metastatic cervical carcinoma has very poor prognosis, mainly because there is no effective systemic therapy which would increase the duration of survival. Biologic agents have recently been found to have activity in cervical carcinoma. The combination of interferon (IFN)-α and 13-cis-retinoic acid has additive and synergistic antitumor activity. Both have antiviral, immunoregulatory and antiangiogenic properties, and are known to modulate malignant cell differentiation and proliferation. We report two patients with recurrent squamous cell carcinoma (SCC) of the cervix who had small-volume progressive metastatic disease, and were treated with a combination of IFN-α and 13-cis-retinoic acid. The first patient had pelvic lymph node metastases and the other had lung metastases. The previously progressive diseases remained stable for a prolonged period of time, 3 and 4 years, with a good quality of life. These cases suggest the possibility of using IFN-α and 13-cis-retinoic acid as a treatment for small-volume residual disease or as postinduction therapy in patients at high risk for disease recurrence.en_US
dc.identifier.citationAnti-Cancer Drugs. Vol.7, No.7 (1996), 800-804en_US
dc.identifier.doi10.1097/00001813-199609000-00014en_US
dc.identifier.issn09594973en_US
dc.identifier.other2-s2.0-10544233360en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/17576
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=10544233360&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleProlonged stabilization of progressive squamous cell cancer of the cervix with interferon-α and 13-cis-retinoic acid: Report of two cases and review of the literatureen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=10544233360&origin=inwarden_US

Files

Collections